Nektar Therapeutics

NKTR

$57.06

Name : Nektar Therapeutics

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,948,199,168.00

EPSttm : -6.29

Nektar Therapeutics

$57.06

3.91%

$2.32

NKTR — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

17.35

Margin Of Safety %

Put/Call OI Ratio

0.44

EPS Next Q Diff

-1.69

EPS Last/This Y

1.54

EPS This/Next Y

-2.01

Price

57.08

Target Price

141.4

Analyst Recom

1.33

Performance Q

-10.35

Upside

-252.6%

Beta

-0.81

Ticker: NKTR

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-08-28	NKTR	72.71	0.24	0.17	41145
2026-08-31	NKTR	71.42	0.24	0.05	42628
2026-09-02	NKTR	72.65	0.23	0.34	43693
2026-09-03	NKTR	76.38	0.23	0.46	43846
2026-09-04	NKTR	74.08	0.24	0.12	45046
2026-09-08	NKTR	75.39	0.24	0.03	46080
2026-09-09	NKTR	73.47	0.26	0.46	47070
2026-09-10	NKTR	70.74	0.26	0.21	48245
2026-09-11	NKTR	69.89	0.26	0.15	48340
2026-09-14	NKTR	68.43	0.27	0.15	47826
2026-09-15	NKTR	66.76	0.27	0.05	48100
2026-09-16	NKTR	67.37	0.27	1.25	48990
2026-09-17	NKTR	69.35	0.25	0.06	48741
2026-09-18	NKTR	67.09	0.23	0.37	52049
2026-09-21	NKTR	66.76	0.29	1.19	32747
2026-09-22	NKTR	61.02	0.34	0.88	35863
2026-09-23	NKTR	57.67	0.43	0.55	40937
2026-09-24	NKTR	59.28	0.45	0.04	45982
2026-09-25	NKTR	57.57	0.44	1.01	47559
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-08-28	NKTR	71.88	-20.9	-	-8.46
2026-08-31	NKTR	71.42	-20.9	-	-8.46
2026-09-01	NKTR	71.89	-20.9	-	-8.46
2026-09-02	NKTR	72.75	-20.9	-	-8.46
2026-09-03	NKTR	75.36	-20.9	-	-8.46
2026-09-04	NKTR	74.14	-20.9	-	-8.46
2026-09-08	NKTR	75.44	-20.9	-	-8.46
2026-09-09	NKTR	73.36	-20.9	-	-8.46
2026-09-10	NKTR	70.70	-20.9	-	-8.46
2026-09-11	NKTR	69.79	-20.9	-	-8.46
2026-09-14	NKTR	68.46	-20.9	-	-8.46
2026-09-15	NKTR	66.73	-20.9	-	-8.46
2026-09-16	NKTR	66.73	-20.9	-	-8.46
2026-09-17	NKTR	68.46	-20.9	-	-8.46
2026-09-18	NKTR	67.10	-20.9	-	-8.46
2026-09-21	NKTR	66.76	-20.9	-	-8.46
2026-09-22	NKTR	61.00	-20.9	-	-8.46
2026-09-23	NKTR	57.68	-20.9	-	-8.46
2026-09-24	NKTR	59.33	-20.9	-	-8.46
2026-09-25	NKTR	57.08	-15.9	-	-8.19
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-08-28	NKTR	-2.87	30.76	18.67
2026-08-31	NKTR	-2.88	31.02	18.67
2026-09-01	NKTR	-2.88	31.02	18.67
2026-09-02	NKTR	-2.88	31.02	18.67
2026-09-03	NKTR	-2.88	31.02	18.67
2026-09-04	NKTR	-2.88	31.02	18.67
2026-09-08	NKTR	-2.88	31.11	18.67
2026-09-09	NKTR	-2.88	31.11	18.67
2026-09-10	NKTR	-2.88	31.11	18.67
2026-09-11	NKTR	-2.91	31.11	18.36
2026-09-14	NKTR	-2.91	31.34	18.36
2026-09-15	NKTR	-2.91	31.34	18.36
2026-09-16	NKTR	-2.91	31.34	18.36
2026-09-17	NKTR	-2.91	31.34	18.36
2026-09-18	NKTR	-2.91	31.34	18.36
2026-09-21	NKTR	-2.91	31.33	18.36
2026-09-23	NKTR	-2.91	31.33	18.36
2026-09-24	NKTR	-2.91	31.33	18.36
2026-09-25	NKTR	-2.91	31.33	17.35
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.23

Avg. EPS Est. Current Quarter

-2.17

Avg. EPS Est. Next Quarter

-2.92

Insider Transactions

-2.91

Institutional Transactions

31.33

Beta

-0.81

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

80.4

Max Drawdown 5-Year %

-97.8

Target Price

141.4

P/E

Forward P/E

PEG

P/S

35.69

P/B

2.16

P/Free Cash Flow

EPS

-6.7

Average EPS Est. Cur. Y

-8.19

EPS Next Y. (Est.)

-10.2

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-287.84

Relative Volume

2.59

Return on Equity vs Sector %

-43.7

Return on Equity vs Industry %

-24.1

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.27

EBIT Estimation

◆ NKTR Healthcare

$57.06

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

13/25

Volume

3/15

Valuation

12/20

TP/AR

2/10

Options

7/10

RSI

27.1

Range 1M

Sup Dist

1.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

13/25

Growth

16/30

Estimates

0/20

Inst/Vol

9/15

Options

4/10

EPS Yr

16.9%

EPS NY

-26.8%

52W%

31.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +147.8% upside

Quality

6/30

Valuation

16/30

Growth

10/25

Stability

9/10

LT Trend

3/5

Upside

+147.8%

Quality

NKTR — P/E HistoricalBiotechnology

Nektar Therapeutics

Sector: Healthcare

Industry: Biotechnology

Employees: 63

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR

Latest News

—

Caricamento notizie per NKTR…

stock quote shares NKTR – Nektar Therapeutics Stock Price stock today

news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025

marketwatch NKTR – Nektar Therapeutics yahoo finance google finance

stock history NKTR – Nektar Therapeutics invest stock market

stock prices NKTR premarket after hours

ticker NKTR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NKTR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y